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Abstract: The aim of this retrospective study is to assess any association between abdominal CT
findings and the radiological stage of COVID-19 pneumonia, pulmonary embolism and patient
outcomes. We included 158 adult hospitalized COVID-19 patients between 1 March 2020 and 1 March
2021 who underwent 206 abdominal CTs. Two radiologists reviewed all CT images. Pathological
findings were classified as acute or not. A subset of patients with inflammatory pathology in
ACE2 organs (bowel, biliary tract, pancreas, urinary system) was identified. The radiological stage
of COVID pneumonia, pulmonary embolism, overall days of hospitalization, ICU admission and
outcome were registered. Univariate statistical analysis coupled with explainable artificial intelligence
(AI) techniques were used to discover associations between variables. The most frequent acute
findings were bowel abnormalities (n = 58), abdominal fluid (n = 42), hematomas (n = 28) and acute
urologic conditions (n = 8). According to univariate statistical analysis, pneumonia stage > 2 was
significantly associated with increased frequency of hematomas, active bleeding and fluid-filled colon.
The presence of at least one hepatobiliary finding was associated with all the COVID-19 stages > 0.
Free abdominal fluid, acute pathologies in ACE2 organs and fluid-filled colon were associated with
ICU admission; free fluid also presented poor patient outcomes. Hematomas and active bleeding
with at least a progressive stage of COVID pneumonia. The explainable AI techniques find no strong
relationship between variables.
Keywords: COVID-19; SARS-CoV-2; abdominal imaging findings; abdominal symptoms
1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported in Wuhan, China, in
December 2019 and is still ongoing. It has resulted in more than 104 million cases and over
2.0 million deaths worldwide, as reported by WHO [1].
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SARS-CoV-2 is an RNA virus genetically located within the genus Betacoronavirus
that uses a glycoprotein (spike protein) to bind to the angiotensin-converting enzyme
2 (ACE2) receptor in order to enter into the cell [2,3]. ACE2 receptors are broadly expressed
in the human body viscera, predominantly in type II pneumocytes of pulmonary alveoli.
This may result in a wide range of direct targets for the virus, ranging from the lungs to the
gastrointestinal system [4].
Accordingly, alongside common clinical features such as fever, cough and myalgia or
fatigue, COVID-19 patients may present with and/or develop atypical clinical presenta-
tions, including gastrointestinal (GI) symptoms [5].
A multicenter and cross-sectional study demonstrated that approximately 50% of
patients experienced symptoms such as diarrhea, nausea, vomiting and abdominal pain [6].
Two recent meta-analyses by Cheung et al. [7] and Parasa et al. [8] showed that the fecal
positivity rate for COVID-19 was 40.5% and 48.1%, respectively.
Given the widening recognition of abdominal manifestations, recent studies reported
the abdominopelvic findings on CT scans in COVID-19 patients with abdominal symp-
toms [9–11]. Imaging findings may lead to a greater understanding of the pathogenesis of
abdominal phenomena in SARS-CoV-2 infection.
The purpose of this study is to assess any association between abdominal CT findings
and the radiological stage of COVID-19 pneumonia, the presence of pulmonary embolism
and patients’ outcome, in terms of overall days of hospitalization, admission in ICU and
patient’s survival/death.
2. Materials and Methods
2.1. Patients Population
This study was approved by the institutional review board of our Hospital and was in
compliance with the Health Insurance Portability and Accountability Act. All aspects of
the study were performed in accordance with the Declaration of Helsinki.
We queried our electronic radiologic database to include in our study population all
adult patients (>18 year old) who consecutively underwent abdominal CT during their
hospitalization between 1 March 2020 and 1 March 2021 and who were positive to real-time
reverse transcriptase polymerase chain reaction (RT-PCR) on throat swabs for COVID-19.
The demographics and clinical characteristics of the patients were obtained by review of
electronic medical records. Age, sex, date of diagnosis, duration of hospitalization, whether
the patient was admitted to intensive care unit (ICU) and whether the patient was deceased
during the admission were noted.
The evidence of pulmonary embolism on the chest CT executed before or during
abdominal imaging was registered.
Stage of COVID-19 pneumonia at the time of abdominal imaging, based only on
radiological features in accordance with data from the published literature [12,13], was
recorded as follows: no COVID-19 pneumonia (stage 0); early/initial stage (stage 1);
progressive stage (stage 2); peak stage (stage 3); absorption stage (stage 4).
2.2. Image Acquisition
All CT scans were performed on a 128-slice (Somatom Definition Flash, Siemens AG,
Forchheiem, Germany) multidetector CT scanner with or without intravenous contrast
media. Scans were obtained during full inspiration in the supine position using the
following parameters: 128 × 0.625 mm or 64 × 0.625 mm, tube voltage of 120 kVp and
tube current of 180–200 mAs. In patients undergoing contrast material-enhanced CT, axial
acquisition of the abdomen and the pelvis was performed after the injection of 80–120 mL
of iodinated contrast media (370 mg of iodine per milliliter, Iopamiro, Bracco Imaging Italia
s.r.l., Milan, Italy) at different phases (arterial, portal and delayed phases) depending on
clinical indication.
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2.3. Image Analysis
All the available CT scans of the abdomen and pelvis were reviewed by two radiolo-
gists in consensus (with 17 and 19 years of experience in radiology) who were blinded to the
radiology reports and to clinical data but were aware of positive RT-PCR test for COVID-19.
All pathological findings were noted and classified as acute or not. We considered
acute abdominal finding any inflammatory condition, obstruction, thrombosis or hemor-
rhage that could cause acute symptoms. A subset of patients with inflammatory pathology
in organs with high ACE2 receptor expression (bowel, biliary tract, pancreas, urinary
system) was identified. Non-acute pathologies such as steatosis, hepatomegaly, cirrhosis,
splenomegaly and cancer were also noted.
Dates of examinations and clinical indications were recorded.
All the images were reviewed on Picture Archiving Communication System (PACS,
Fuji by Fujifilm Company LTD, Tokyo, Japan).
2.4. Explainable AI for Causal Inference
To discover whether the COVID-19 pneumonia stage, pulmonary embolism (PE)
and/or admission at intensive care unit (ICU) were associated with any abdominal finding,
we applied both univariate statistical tests and explainable artificial intelligence (AI) techniques.
Since the data contained few missing values (the 0.025 of missing values), “AI explana-
tions” were computed over an imputed dataset, where missForest algorithm [14] was used
for the imputation. Next, we considered each abdominal finding as a target to be predicted
based on linear or complex associations between the following variables: pneumonia stage
(stage > 0, stage > 1, stage > 2, stage > 3), PE and/or admission to ICU.
To detect any association between the presence of abdominal findings and the patient
outcome (death, number of days of hospitalizations >15, number of days of hospitalizations > 30),
we used the abdominal findings as variables to predict any patient outcome.
To produce preliminary explanations and assess individual variables, we initially
computed the performance of each variable when used alone in the prediction of any of the
outcome variables. To this aim, we used each variable as the unique predictor and assessed
it by averaging Sensitivity (Sens), Specificity (Spec), Accuracy (Acc), F1-score (F1), Positive
Predictive Value (PPV) and Negative Predictive Value (NPV) over 1000 stratified holdouts
with train:test proportion equal to 70:30 (for each integer variable and each train–test split,
the best threshold was found on each training set by maximizing the Youden index).
Next, explanations considering variable interactions were produced by averaging
the results of 100 repetitions of stratified ten-fold cross-validation, the latest being used
in each iteration to obtain unbiased estimates. More precisely, feature selection was
initially applied to each training set. To this aim, univariate statistical tests were ex-
ploited, where a chi-square test or Wilcoxon rank-signed test at the 95% confidence level
(p-value < 0.05) were applied for boolean (absence or presence of a specific condition) and
integer variables, respectively.
Next, statistically significant variables (p-value < 0.05) were used to train eXplainable
Artificial Intelligence (XAI) models that can produce explanations in terms of variable
importance. More precisely, Logistic Regression classifiers (LR) [15], Generalized Linear
Models (GLM) [16], Decision Tree classifiers (DT) [17], Random Forest classifiers (RF) [18]
and K-nearest Neighbor classifiers (KNN) [19] were experimented. For GLMs, RFs, DTs and
KNNs, the model hyper-parameters were chosen by applying Bayesian optimization [20]
operated through an internal 5-fold cross-validation. Each classifier performance was then
evaluated by measuring Sensitivity (Sens), Specificity (Spec), Accuracy (Acc), F1-score (F1),
Positive Predictive Value (PPV) and Negative Predictive Value (NPV), where classification
tasks obtaining an accuracy lower than 0.5 were discarded, since a random choice would,
on average, achieve better performance. F1 score, followed by considerations about the
balance of sensitivity and specificity, were used to identify the best classifier models. The
relative variables’ importance for each prediction task were identified by analyzing the
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estimated coefficients for LR and GLMs, or the variable importance estimated by using
permutation analysis for RFs, DTs and KNNs.
3. Results
During the study period, 158 adult patients who tested positive for SARS-CoV-2
underwent 206 abdominal CTs. Patients included 99 men (63%) and 59 women (37 %),
with an average age of 66 ± 16 years (range 18 to 95 years). Age and sex were not linearly
associated with any abdominal findings. In our cohort of 158 patients, 168 CTs were
requested for the onset of abdominal symptoms or changes in the abdominal clinical
situation and 38 for follow-up evaluation. The main study indications are summarized in
Figure 1.
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distributions (p-values ≈ 0), while age distributions was by no means different for different 
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Radiological stages of COVID-19 pneumonia at time of the 168 abdominal imaging,
excluding f llow up-studies, were: no COVID-19 pneumonia (stage 0, n = 32, 19%) or
resolved pneumonia (n = 3, 2%), i itial pneumonia (stage 1, n = 4, 2%), progressive
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(stage > 0, stage > 1, sta e > 2) we found a atistic ll significant difference between th
sex distributions (p-values ≈ 0), while ge distributions was by no means different for
fferen stages (p-values > 0.05).
Regarding patient outcomes, 20 (13%) patients were admitted to intensive care units
(ICU) and 20 (13%) died. Patient were hospitalized for an average of 38 ± 27 days (ra ge,
3 to 130 ays).
The presence of at least one acute pathology in organs with high ACE2 receptor
expression was ass ci ted with admission to ICU (p-value = 0.0238).
We noted 59 bowel abnormalities i 168 abdominal CT images. In 33 patients, the
presence of fluid-filled colo suggestive of diarrhea was associated with ICU admission
(p = 0), days of hospitalization more than 30 (p = 0.04) and stage of COVID pneumonia
greater than 2 (p = 0.02). No associations were found with bowel wall thickening with CT
signs of colitis (n = 11), enteritis (n = 5) or bowel perforation (n = 3). A frequent finding was
free abdominal fluid (n = 42) that was associated with ICU admission (p-value = 0) and
death (p = 0.02).
Other notable abdominal findings were hematomas (n = 28) and active bleeding
(n = 14), which, according to univariate statistical tests, had a significant association with
presence of pneumonia stage > 2 (p = 0.0051 and p = 0.03).
The presence of at least one hepatobiliary finding in 50 patients was associated with
the presence of COVID pneumonia (stage > 0).
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No associations between abdominal findings and pulmonary embolism were found.
Abdominal imaging findings and related p-values are summarized in Figure 2. In
order to improve the reproducibility of the study, their definition is reported in Appendix A.
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4. Discussion
While SARS-CoV-2 has been established as a respiratory tract pathogen, causing non-
productive cough, shortness of breath and fever, its pathogenesis may also be responsible
for gastrointestinal manifestations, such as diarrhea, nausea, vomiting and abdominal
pain [5,6].
Given the widening recognition of abdominal manifestations, recent studies reported
the abdominopelvic findings on CT scans in COVID-19 patients with abdominal symp-
toms [9–11].
Following the discovery that the SARS-CoV-2 virus targets host cells expressing
ACE-2 receptors [2,3], including the cells of the gastrointestinal tract (certain intestinal cells,
cholangiocytes and hepatocytes), major interest has recently been focused on the virus role
in dysregulating the digestive system, hepatobiliary function and pancreatic function.
We found that CT signs of acute pathology in abdominal organs with high ACE2
receptor expression were associated with ICU admission.
The presence of at least one hepatobiliary imaging finding was associated with all
the progressive COVID-19 pneumonia stages but was not associated with ICU admis-
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sion, even if these findings are common in critically ill patients admitted in the ICU [21].
However, as recently reported by Nardo et al. [22], hepatobiliary findings may also be
related to immune-mediated liver damage and cholangiocellular injury due to the severe
inflammatory response/systemic inflammatory response syndrome (SIRS) in COVID-19.
Chai et al. [23] found that ACE2 expression levels in bile duct cells were slightly higher
than those in liver cells and were comparable with alveolar epithelial type II cells; these
expression levels revealed the possibility for direct infection of cholangiocytes by SARS-
CoV-2. They also suggested that liver abnormalities of COVID-19 patients may be due
cholangiocyte dysfunction since cholangiocytes play critical roles in liver regeneration and
immune responses [24]
In Shiralkar et al.’s study [10], bowel abnormalities, including acute pancreatitis and
acute cholecystitis, were seen in 25% of patients. In our study, 27% of patients had bowel ab-
normalities, but there was only one case of pancreatitis, acute cholecystitis and cholangitis.
Similarly, Bhayana et al. demonstrated a spectrum of abdominopelvic imaging find-
ings that correlated with COVID-19 infection with the predominant imaging findings of
bowel wall thickening (31%) [11]. The incidence of bowel abnormalities was also high in the
study by Tirumani et al., where abnormal bowel wall was seen in 18.1% of cases, fluid-filled
colon in 16.7% of patients and severe colitis was seen only in one patient (1.4%) [9]. We
found that a fluid-filled colon was significantly associated with ICU admission, a longer
period of hospitalization (more than 30 days) and a progressive stage of COVID pneumonia
(>2). Moreover, the presence of free abdominal fluid, which was a frequent finding, was
associated with ICU admission and death.
Two recent meta-analyses showed that there is a high incidence of fecal positivity rate
in COVID-19 infection (nearly 40–48%), though the prevalence of GI symptoms is seen
only in a few patients (4–12%) [7,8].
A recent study by El Moheb et al. showed that a higher rate of gastrointestinal
complications was found in critically ill COVID-19 patients compared with propensity
score-matched patients without COVID-19 [25].
ACE2 receptors are expressed in enterocytes of the small intestine and vascular
endothelium, suggesting that the small bowel and vasculature may be susceptible to
SARS-CoV-2 infection [2,3]. However, there are still many open questions about the poten-
tial pathophysiological mechanisms for SARS-CoV-2 bowel tropism.
In our study, no associations were identified between bowel wall thickening and the
presence of COVID pneumonia, pulmonary embolism or patient’s outcome. However,
in four patients, endoscopic biopsy identified ischemic mucosal necrosis, indicating that
SARS-CoV-2 might have played an active role in relevant intestinal hypoperfusion, but
no vascular causes were clearly identified at CT. Funt et al. [26] also depicted microbial
metabolites and endotoxins released into the blood from lung inflammation can alter the
microbiome of the gut leading to abdominal symptoms in the so-called “gut-lung” axis.
In our study, according to univariate statistical analysis, COVID-19 pneumonia
stage > 2 defined at the time of abdominal imaging acquisition was significantly asso-
ciated with increased frequency of at least one hepatobiliary finding, hematomas, active
bleeding and a fluid-filled colon.
ACE2 receptors are expressed on kidney podocytes and proximal convoluted tubules
cells, suggesting a potential role of SARS-CoV-2 infection in the pathophysiology of acute
renal failure due to a direct virus-induced cytopathic effect [27]; however, in our cohort of
patients, no statistically significant association was found.
Zaim et al. [28] reported that up to 19% of patients with COVID-19 have acute renal
dysfunction. This must be taken into consideration before administering contrast agents
for CT and MRI studies in COVID-19 patients.
In our study, no statistically significant associations were found between COVID-19
patients who developed pulmonary embolism (PE) during their hospitalization and acute
inflammatory findings in abdominal organs with high ACE2 receptors. Currently, in
coronavirus disease (COVID-19), the origin of endothelial dysfunction that may lead to PE
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is not known. As reported by Rodriguez et al. [29], the endothelium of pulmonary arteries
appears to be highly sensitive to SARS-CoV-2 infection, given its expression of the ACE-2
receptor. However, endothelial dysfunction could also occur secondarily to the activation
of inflammatory and/or coagulation and complement cascades [29]. We theorize that this
second mechanism may explain better the absence of association with acute inflammatory
imaging findings in abdominal organs with high ACE2 receptors. The limitations of the
study include its retrospective nature, the small sample size, the absence of pathologic
correlation and the lack of fecal COVID-19 testing.
There are still many questions about the mechanisms underlying the pathophysiology
of SARS-CoV-2 infection, and larger prospective studies with histopathologic correlation
are required to understand the pathogenesis of these abdominopelvic imaging findings
better [9–11].
5. Conclusions
Abdominal Abnormalities Were Common Findings in COVID-19 Patients
We found some statistical associations between abdominal findings and patients’
outcomes or stages of COVID pneumonia. In particular, the presence of acute pathology
in abdominal organs with high ACE2 receptors was significantly associated with ICU
admission. Moreover, explainable AI techniques did not find any strong relationships
between the analyzed variables; therefore, further investigations are required.
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Appendix A
To improve the reproducibility of our study, in this appendix, we provide the main
definitions (and their source) for the abdominal image findings we identified in the patient
cohort used in this study.
Acute cholecystitis [30]: Acute cholecystitis is one of the complications of cholelithiasis
due to stones getting impacted and persistently obstructing the cystic duct. This results
in inflammation and in the consequent release of inflammatory enzymes, which worsen
damages in the mucosa and eventually cause ischemia, promote bacterial infection and
may ultimately result in necrosis and perforation. Acute cholecystitis causes a fibrotic and
contracted gallbladder, unable to concentrate bile and empty it.
Acute nephropathy or Acute renal failure [31,32]: Acute renal failure is due to a
rapid fall in the rate of glomerular filtration, which manifests clinically as an abrupt and
sustained increase in the serum levels of urea (by >0.3 mg/dL (X26.5 lmol/L) within 48 h)
and creatinine (to >1.5 times baseline) with an associated disruption of salt and water
homeostasis and a reduced urine volume (<0.5 mL/kg/h for 6 h).
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Biliary dilatation (dilation) [33]: Bile is a substance (produced by the liver and accu-
mulated in the gallbladder) that is involved in the digestion of fats. For this reason, it is
brought into the intestines through the bile ducts (biliary ducts) when food is ingested. As
a consequence of injury or surgery, the biliary ducts may become narrower and narrower
until becoming stuck. In this case, the procedure of biliary dilation has the effect of reopen-
ing biliary ducts to avoid consequences such as bile duct inflammation (cholangitis), liver
abscess or secondary cirrhosis.
Bowel bleeding [34]: Gastrointestinal bleed includes upper GI tract bleeds (about
50% of GI bleeds), lower GI tract bleeds (40%) and bleeds due to vascular lesions in
the small bowel (about 5% to 10%). Clinically, it manifests with visible bleeding, either
melena or hematochezia, or occult bleeding, when there is no gross bleeding, but signs
and symptoms of anemia (fatigue, dyspnea or palpitations) are present. The management
options for GI bleeding involve conservative, radiological, pharmacologic, endoscopic and
surgical methods.
Bowel wall thickening [35]: The normal bowel wall measures between 1 and 2 mm
for the small bowel and less than 3 mm for the colon. However, it must be considered
that the thickness of the normal bowel wall can vary depending on the degree of luminal
distention. Bowel wall thickening may be due to normal variants, inflammatory conditions
and neoplastic disease.
Cholangitis [36]: Acute cholangitis is caused by an ascending bacterial infection
of the biliary tree, usually due to the presence of stones in the common bile duct, that
leads to partial or complete obstruction of the biliary system, with an increased risk of
superinfection. If not treated, it can lead to septic shock. Depending on the course and
severity, a biliary drainage procedure may be performed.
Cholelithiasis and biliary sludge [37]: Cholelithiasis is the presence of one or more
stones in the gallbladder. It is usually asymptomatic; when symptomatic, it manifests
with biliary colic. More serious complications include biliary tract obstruction, infection
(cholangitis and/or cholecystitis) and gallstone pancreatitis.
Biliary sludge is made of calcium bilirubinate (a polymer of bilirubin), cholesterol
microcrystals and mucin. It develops during gallbladder stasis, and it is often a precursor
of gallstones.
Chronic hepatitis [38]: Chronic hepatitis is defined as hepatitis that lasts over 6 months.
It can be caused by hepatitis B and C viruses, nonalcoholic steatohepatitis (NASH), alcohol-
related liver disease and autoimmune liver disease (autoimmune hepatitis). It may present
with cirrhosis or its complications, such as portal hypertension. Treatment varies upon the
underlying condition. Liver transplantation can be indicated.
Cystitis [39]: Cystitis is the inflammation of the lining of the bladder. Common causes
include urinary infection, medicines (such as anticancer drugs) or chemicals (such as
perfumes or dyes), radiation therapy, long-term urinary catheterization and underlying
conditions, such as diabetes, kidney stones, enlarged prostate or a spinal cord injury.
Clinically, it manifests with pain and a burning feeling while urinating, blood in the urine
and dark or cloudy urine.
Hematoma [40]: Hematoma is defined as a pool of mostly clotted blood in an organ,
tissue or body space. It is caused by a vascular lesion due to surgery or an injury that leads
to blood leaking into the surrounding space. Hematomas may resolve spontaneously over
time as the blood debris is removed. Surgically removing or evacuating the blood becomes
necessary based on its symptoms or location.
Hepatomegaly [41]: Hepatomegaly is an enlarged liver. Its size varies with sex and
body size, but it usually extends from the fifth intercostal space to the right costal margin
in the midclavicular line. By ultrasound, a liver span >16 cm in the midclavicular line is
indicative of hepatomegaly.
Pancreatitis [42]: Acute pancreatitis is an acute response to injury of the pancreas. The
most common causes include gallstones (35% to 40% of cases), alcohol use (30% of cases),
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autoimmune pancreatitis, hypertriglyceridemia, post-endoscopic retrograde cholangiopan-
creatography (ERCP), genetic risk, pancreatic duct injury, medication and drugs.
Chronic pancreatitis is defined as a continuing inflammatory disease of the pancreas,
characterized by irreversible morphologic changes that can result in permanent organ
damage. Alcohol has been identified as a definitive cause of chronic pancreatitis.
Paralytic ileus [43]: Paralytic ileus is characterized by the dilation of the bowel in
the absence of mechanical obstruction. Clinically, it manifests with nausea, vomiting,
abdominal distension and obstipation; on x-ray or CT imaging with bowel dilation. Causes
are usually infectious, metabolic, neurologic (linked to dysregulation of the autonomic
nervous system), autoimmune, iatrogenic (recent surgery) or idiopathic.
Periportal edema [44]: Periportal edema is related to passive congestion or diminished
perfusion of the liver, usually attributable to hepatic injury. It can be associated with
Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, passive congestion due
to heart failure, hepatic infarction and ischemic hepatitis.
Portal vein thrombosis [45]: Portal vein thrombosis is the occlusion of the portal vein
(formed by the confluence of the splenic and the mesenteric veins, which drain the spleen
and the intestine, respectively) by a thrombus (clotted blood). It typically occurs in patients
with cirrhosis and/or prothrombotic disorders. When chronic, it can lead to collateral
circulation (e.g., cavernous portal transformation) or portal hypertension.
Renal infarction [46]: Renal infarction results from interruption of the arterial supply
(either the main renal artery or the smaller segmental branch arteries) to the kidney. Com-
mon causes include cardioembolic disease, renal artery injury (e.g., arterial dissection),
hypercoagulable states, thromboembolism and in situ thrombosis. Depending upon the
severity, renal infarction can lead to renovascular hypertension, chronic kidney disease and
end-stage kidney disease.
Steatosis [47]: Steatosis is defined as fatty infiltration of the liver due to insulin
resistance associated with central obesity and a sedentary lifestyle. In the early stages, it
is reversible. If not treated, steatosis may progress to steatohepatitis, which can lead to
progressive hepatic injury and fibrosis.
Vein thrombosis [48]: A vein thrombosis is a blood clot (thrombus) that forms within
the veins. It is usually associated with increased blood viscosity, reduced blood flow,
increased venous pressure, genetic deficiencies and acquired and constitutional factors.
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